SG10201508159SA - Factor II And Fibrinogen For Treatment Of Haemostatic Disorders - Google Patents

Factor II And Fibrinogen For Treatment Of Haemostatic Disorders

Info

Publication number: SG10201508159SA
Authority: SG; Singapore
Prior art keywords: fibrinogen; factor; treatment; haemostatic disorders; haemostatic
Prior art date: 2010-10-06

Application number

SG10201508159SA

Inventor

Ann Lovgren

Kenny Hansson

Original Assignee

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-06

Filing date

2011-09-19

Publication date

2015-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201508159S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-19 Application filed by Medimmune Ltd filed Critical Medimmune Ltd

2015-10-29 Publication of SG10201508159SA publication Critical patent/SG10201508159SA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Hematology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

SG10201508159SA 2010-10-06 2011-09-19 Factor II And Fibrinogen For Treatment Of Haemostatic Disorders SG10201508159SA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39022410P	2010-10-06	2010-10-06

Publications (1)

Publication Number	Publication Date
SG10201508159SA true SG10201508159SA (en)	2015-10-29

Family

ID=44677879

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201508159SA SG10201508159SA (en)	2010-10-06	2011-09-19	Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
SG2013021498A SG188639A1 (en)	2010-10-06	2011-09-19	Factor ii and fibrinogen for treatment of haemostatic disorders

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG2013021498A SG188639A1 (en)	2010-10-06	2011-09-19	Factor ii and fibrinogen for treatment of haemostatic disorders

Country Status (16)

Country	Link
US (1)	US9433664B2 (en)
EP (1)	EP2624859B1 (en)
JP (1)	JP6000259B2 (en)
KR (1)	KR20130136988A (en)
CN (1)	CN103221061A (en)
AU (1)	AU2011313505B2 (en)
BR (1)	BR112013008034A2 (en)
CA (1)	CA2812888A1 (en)
DK (1)	DK2624859T3 (en)
ES (1)	ES2625153T3 (en)
HU (1)	HUE033204T2 (en)
MX (1)	MX343784B (en)
PL (1)	PL2624859T3 (en)
RU (1)	RU2606155C2 (en)
SG (2)	SG10201508159SA (en)
WO (1)	WO2012045569A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103221061A (en)	2010-10-06	2013-07-24	米迪缪尼有限公司	Factor II and fibrinogen for treatment of haemostatic disorders
IL230150A0 (en)	2013-12-24	2014-09-30	Omrix Biopharmaceuticals Ltd	One component fibrin glue comprising zymogens
DK3579857T3 (en) *	2017-02-09	2022-06-07	Csl Behring Gmbh	A BLOOD COAGULATION FACTOR SUBSTITUTE PRODUCT FOR USE IN THE TREATMENT OR PROPHYLAXATION OF BLEEDING
CN116059431A (en) *	2021-10-29	2023-05-05	丁琴琴	Double-layer hemostatic dressing containing blood coagulation factors and preparation method thereof
WO2023220412A1 (en) *	2022-05-13	2023-11-16	Cedars-Sinai Medical Center	Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1981002105A1 (en) *	1980-01-28	1981-08-06	Baxter Travenol Lab	Therapeutic compositions & methods for manufacture and use
US4501731A (en)	1983-06-27	1985-02-26	Tishkoff Garson H	Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (en) *	1994-08-26	1996-02-29	Behringwerke Ag	Medicament, which is suitable as an antidote for blood anticoagulants and its use
DK0796623T3 (en) *	1996-03-20	2005-08-01	Baxter Ag	Pharmaceutical composition for the treatment of blood clotting disorders
AT409334B (en) *	1997-09-19	2002-07-25	Immuno Ag	PHARMACEUTICAL PREPARATION CONTAINING VITAMIN K-DEPENDENT INDIVIDUAL FACTORS
US7094428B2 (en)	2000-06-16	2006-08-22	The University Of Medicine And Dentistry Of New Jersey	Hemostatic compositions, devices and methods
US6825323B2 (en)	2001-01-10	2004-11-30	The United States Of America As Represented By The Secretary Of The Army	Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
IL156842A0 (en)	2001-02-05	2004-02-08	Novo Nordisk Healthcare Ag	Combined use of factor vii polypeptides and factor ix polypeptides
US20060025336A1 (en)	2001-07-16	2006-02-02	Novo Nordisk A/S	Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
HUP0400976A3 (en)	2001-07-20	2006-01-30	Novo Nordisk Healthcare Ag	Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
US20040101546A1 (en)	2002-11-26	2004-05-27	Gorman Anne Jessica	Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
AU2003303522B2 (en)	2002-12-31	2009-05-28	Marine Polymer Technologies, Inc.	Hemostatic compositions and uses therefor
GB0324044D0 (en)	2003-10-14	2003-11-19	Astrazeneca Ab	Protein
US7211559B2 (en)	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
EP1748781B1 (en)	2004-05-27	2012-12-19	Baxter International Inc.	Methods for treating bleeding disorders using sulfated polysaccharides
WO2006114105A2 (en)	2005-04-26	2006-11-02	Maxygen Holdings Ltd.	Use of modified factor vii for treating bleeding
MX336958B (en)	2005-11-15	2016-02-05	Philadelphia Children Hospital	METHODS AND COMPOSITIONS TO MODULATE HEMOSTASIA.
CN101501216B (en) *	2006-03-06	2013-10-02	胡玛基因公司	A method for the preparation of recombinant human thrombin
US20080014251A1 (en)	2006-07-14	2008-01-17	Advanced Vascular Dynamics	Hemostatic compound and its use
US20090148502A1 (en)	2006-10-23	2009-06-11	Hemo Nanoscience, Llc	Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en)	2006-12-22	2008-06-25	CSL Behring GmbH	Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
WO2008121330A1 (en)	2007-03-30	2008-10-09	Thrombodyne, Inc.	Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
WO2008127702A2 (en)	2007-04-13	2008-10-23	Catalyst Biosciences, Inc.	Modified factor vii polypetides and uses thereof
US8852558B2 (en)	2008-03-11	2014-10-07	Materials Modification, Inc.	In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
EP2337793A4 (en)	2008-10-08	2013-04-10	Thrombodyne Inc	Methods of making concentrated fibrinogen- and platelet containing compositions
CN103221061A (en)	2010-10-06	2013-07-24	米迪缪尼有限公司	Factor II and fibrinogen for treatment of haemostatic disorders

2011
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/en active Pending
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 MX MX2013003715A patent/MX343784B/en active IP Right Grant
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/en not_active Expired - Fee Related
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/en active Active
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/en unknown
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 PL PL11761051T patent/PL2624859T3/en unknown
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/en not_active Application Discontinuation
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/en not_active IP Right Cessation
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/en not_active IP Right Cessation
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en active Application Filing

Also Published As

Publication number	Publication date
KR20130136988A (en)	2013-12-13
RU2013120033A (en)	2014-11-20
JP6000259B2 (en)	2016-09-28
EP2624859B1 (en)	2017-03-01
WO2012045569A9 (en)	2016-01-07
AU2011313505A1 (en)	2013-04-11
MX343784B (en)	2016-11-23
WO2012045569A1 (en)	2012-04-12
HUE033204T2 (en)	2017-11-28
US20130280236A1 (en)	2013-10-24
RU2606155C2 (en)	2017-01-10
US9433664B2 (en)	2016-09-06
CN103221061A (en)	2013-07-24
DK2624859T3 (en)	2017-06-06
SG188639A1 (en)	2013-05-31
AU2011313505B2 (en)	2015-09-17
MX2013003715A (en)	2013-09-26
BR112013008034A2 (en)	2016-06-14
PL2624859T3 (en)	2017-09-29
ES2625153T3 (en)	2017-07-18
EP2624859A1 (en)	2013-08-14
CA2812888A1 (en)	2012-04-12
JP2013538863A (en)	2013-10-17

Publication	Publication Date	Title
HK1245130A1 (en)	2018-08-24	Enzyme compositions and use thereof for wound healing
EP2603202A4 (en)	2016-06-01	Compositions and methods for treatment of taupathy
EP2533772A4 (en)	2016-03-16	Methods and compositions for wound healing
ZA201304280B (en)	2014-08-27	Treatment of jak2-mediated conditions
IL226401A0 (en)	2013-07-31	Methods of treating fgf21-associated disorders
EP2554175A4 (en)	2013-08-21	Composition for treatment of damaged part
IL225130A (en)	2017-11-30	Devices for the treatment of vascular defects
ZA201205829B (en)	2013-05-29	Treatment of respiratory disorders
ZA201303810B (en)	2014-11-26	Methods and compositions suitable for promoting healthy skin
EP2654745A4 (en)	2014-03-26	Composition for the treatment of skin conditions
HK1166305A1 (en)	2012-10-26	Compositions and methods for the treatment of inflammation
GB201302653D0 (en)	2013-04-03	Pharmaceutical compositions and methods of treatment
EP2574172A4 (en)	2013-10-30	Materials and methods for treatment of inflammation
IL225793A0 (en)	2013-09-30	Methods and compositions for the treatment of insulin-associated medical conditions
IL256026B (en)	2019-08-29	Methods of treatment
IL225896A0 (en)	2013-06-27	Treatment of mecp2-associated disorders
EP2566483A4 (en)	2013-11-13	Methods and agents for enhancing wound healing
SG10201508159SA (en)	2015-10-29	Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
EP2549867A4 (en)	2013-08-14	Compositions and methods for prevention and treatment of wounds
SG10201510568WA (en)	2016-01-28	Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
EP2635293A4 (en)	2014-04-02	Skin wound healing compositions and methods of use thereof
IL223385B (en)	2020-06-30	Treatment of inflammatory disorders
EP2654793A4 (en)	2015-07-22	Methods and compositions for wound treatment
GB201010638D0 (en)	2010-08-11	Composition for treatment of skin
GB201007205D0 (en)	2010-06-16	Treatment of joint disorders